NVN Liquidation (NVN Liquidation) Growth Rank : 0 (As of Apr. 27, 2024)

View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation Growth Rank?

NVN Liquidation has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

NVN Liquidation Growth Rank Related Terms

Thank you for viewing the detailed overview of NVN Liquidation's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NVN Liquidation (NVN Liquidation) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.

Executives

Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman	director	9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour	director	C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay	officer: VP, Finance & Corp. Controller	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John	officer: EVP, Chief Operating Officer	C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky	director	TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin	director	C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram	director	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer	director	7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak	officer: Chief Accounting Officer	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust	10 percent owner	100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker	10 percent owner	100 SAS CAMPUS DRIVE, CARY NC 27513